Edition:
India

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

67.72EUR
9:05pm IST
Change (% chg)

€0.49 (+0.73%)
Prev Close
€67.23
Open
€67.01
Day's High
€67.90
Day's Low
€66.80
Volume
3,326,662
Avg. Vol
3,514,584
52-wk High
€84.38
52-wk Low
€52.02

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 22.18 29.89 32.67
EPS (TTM): 5.29 -- --
ROI: 8.69 14.89 14.48
ROE: 16.39 16.01 15.78

What are the obstacles to Bayer settling Roundup lawsuits?

Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

7:53pm IST

Explainer: What are the obstacles to Bayer settling Roundup lawsuits?

Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

7:37pm IST

CORRECTED-EXPLAINER-What are the obstacles to Bayer settling Roundup lawsuits?

Aug 22 Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

7:34pm IST

Wall Street rally ends as financial shares slide

NEW YORK Financial shares led U.S. stocks lower on Tuesday to end a three-day rally as investors awaited comments from Federal Reserve Chair Jerome Powell at the end of the week. | Video

21 Aug 2019

Deals of the day-Mergers and acquisitions

Aug 20 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

21 Aug 2019

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health agreed to buy Bayer's veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

20 Aug 2019

UPDATE 3-Elanco to become No.2 in animal health with $7.6 bln Bayer deal

* Elanco gains strength in e-commerce, tick and flea control (Adds shares, Roundup litigation, Elanco rights issue)

20 Aug 2019

Elanco to buy Bayer's animal health unit for $7.6 billion

Aug 20 Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space.

20 Aug 2019

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

17 Aug 2019

UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Aug 16 Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

17 Aug 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates